CN104014000A - Injection reagent for cosmetic filling - Google Patents
Injection reagent for cosmetic filling Download PDFInfo
- Publication number
- CN104014000A CN104014000A CN201410276414.7A CN201410276414A CN104014000A CN 104014000 A CN104014000 A CN 104014000A CN 201410276414 A CN201410276414 A CN 201410276414A CN 104014000 A CN104014000 A CN 104014000A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- wrinkle
- beta
- injection reagent
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to an injection reagent for cosmetic filling, and the injection reagent comprises the following ingredients in percentage by weight: 13-17% of transforming growth factor -beta, 19-23% of platelet-derived growth factor, 9-12% of epidermal growth factor, 2-4% of fibronectin, 2-4% of vitronectin, 32-38% of protease-activated receptor, 1-2% of interleukin 1beta and 2-6% of cross-linking agent. The injection reagent for cosmetic filling is capable of removing frontal cross striation, crow feet, intercilium wrinkle, nasolabial wrinkle, perioral wrinkle and scars, and is free of untoward effects and safe to use.
Description
Technical field
The present invention relates to a kind of beauty treatment injection reagent, particularly a kind of be applied to that beauty treatment fills smooth away wrinkles and eliminate the injection reagent of cicatrix.
Background technology
Tissue transplantation is one of the substance studied of plastic surgery and treatment means, and wherein injection transplantation technology meets the trend of modern minimally invasive surgery development, especially for cosmetic plastic surgery hospitalier, seems particularly necessary.Application injectivity organization material carries out noinvasive, volatile facial filling becomes most popular operational means, but the research and development of Injectable soft tissue filling agent is for cosmetic plastic surgery scholar, is one always and has challenging problem.In recent years, various injectivity soft-tissue material comprises that natural material synthetic and of the same race, xenogenesis is widely used.But for eliminating volume band, crows-feet, glabella stricture of vagina, the muffle stricture of vagina of face, the injection reagent of perioral aging lines at present also in blank.
Summary of the invention
The deficiency existing for prior art, the invention provides and a kind ofly eliminate volume band, crows-feet, glabella stricture of vagina, muffle stricture of vagina, perioral aging lines and cicatrix, has no adverse reaction, uses the safe injection reagent that beauty treatment is filled that is applied to.
For achieving the above object, the invention provides following technical scheme: a kind of injection reagent that is applied to beauty treatment filling, it is characterized in that: include transforming growth factor-beta, platelet derived growth factor, epidermal growth factor, Fn Fiberonectin, vitronectin, Protease-Activated Receptor, interleukin-1 beta and cross-linking agent, each compositions in weight percentage is: transforming growth factor-beta 1 3%-17%; Platelet derived growth factor 19%-23%; Epidermal growth factor 9%-12%; Fn Fiberonectin 2%-4%; Vitronectin 2%-4%; Protease-Activated Receptor 32%-38%; Interleukin-1 beta 1%-2%; Cross-linking agent 2%-6%.
Wherein, cross-linking agent is fibrin.
Adopt technique scheme, the prepared reagent of combination of above-mentioned each component can be eliminated volume band, crows-feet, glabella stricture of vagina and muffle stricture of vagina, perioral aging lines and cicatrix, and uses safety.
The present invention is further set to: also include vascular endothelial cell growth factor and insulin like growth factor, its compositions in weight percentage is: vascular endothelial cell growth factor 1%-3%, IMA-IGF2BP3-001 %-4%.
Adopt technique scheme, the interpolation of vascular endothelial cell growth factor and insulin like growth factor, can eliminate the side effect of reagent, and user has no adverse reaction after using.
The specific embodiment
The present invention is a kind of injection reagent that beauty treatment is filled that is applied to, it is characterized in that: include transforming growth factor-beta, platelet derived growth factor, epidermal growth factor, Fn Fiberonectin, vitronectin, Protease-Activated Receptor, interleukin-1 beta and cross-linking agent, each component adopts conventional method to be evenly mixed with and to form under room temperature state, and each compositions in weight percentage is: transforming growth factor-beta 1 3%-17%; Platelet derived growth factor 19%-23%; Epidermal growth factor 9%-12%; Fn Fiberonectin 2%-4%; Vitronectin 2%-4%; Protease-Activated Receptor 32%-38%; Interleukin-1 beta 1%-2%; Cross-linking agent 2%-6%.The collagen fiber that form due to Fibrinogen can strengthen intercellular sticking, and grow by the migration that provides a fibrous reticular structure to be beneficial to cell, play the support effect in skin histology, so the cross-linking agent optimum fiber albumen in the present invention.Select said components as the formula of reagent, wherein, transforming growth factor-beta major function in the formation of collagen protein is embodied on chemotaxis and mitosis promoting, can stimulate front fibroblastic chemotactic, division, maturation, promote the expression of extracellular matrix and suppress its degraded, form generation, propagation and the differentiation of cell are played an important role.Can suppress the formation of other cell and the absorption of collagen, the deposition of collagen is also had to facilitation; Platelet derived growth factor is the key factor in all creation agglutinations, a kind of potential mitogen and angiogenin, differentiation and growth that can mesenchymal. stimulate division and the migration of vascular endothelial cell to creep, can raise the expression of the other kinds factor and indirectly improve the function of fibroblasts to secrete collagen protein, also can activate collagenase and promote the deposition of collagen stroma; The strong augmentor of epidermal growth factor, division and the increment of Various Tissues cell type in stimulation body promote synthesizing and deposition of extracellular matrix simultaneously; Fn Fiberonectin promote various cells adhesion, prevent the loss of cell; Vitronectin has adhesion and the guiding function of cell; Protease-Activated Receptor has regulating action synthetic and secretion collagen protein; Interleukin-1 beta can be suppressed to fibrocellular synthetic at certain density IL-1 β.And the synthetic minimizing of fibroblast can make the chance of tissue fibering reduce to a certain extent.Can infer thus, IL 1 by being suppressed to the synthetic of fibrocyte collagen protein, can reduce to a certain extent the abnormal deposition of collagen in fibrotic disease process, thereby suppresses the formation of cicatrix.In sum, IL-1 β can be suppressed to the expression of fibrocyte mRNA and synthesize, and is reduced to fibrocellular synthesizing, and the chance of collagen abnormal deposition is reduced, thereby the formation of cicatrix and tissue accumulation is played to certain inhibitory action.
In embodiments of the present invention, in order to make user, after use, eliminate untoward reaction and side effect, further added vascular endothelial cell growth factor and islets of langerhans rope like growth factor, and these two groups of compositions in weight percentage are: vascular endothelial cell growth factor 1%-3%, IMA-IGF2BP3-001 %-4%.Because vascular endothelial cell growth factor is by autocrine and paracrine and Surface of Vascular Endothelial Cells receptors bind, promote the increment of endotheliocyte, the formation of induction new vessels, for regeneration and the metabolism of local organization provides favourable microenvironment; Insulin like growth factor has the mitosis of irritation cell, the expression of Cell differentiation inducing activity and promotion differentiation function.There is the function of coordinate expression with PDGF, so select the vascular endothelial cell growth factor of suitable ratio and insulin like growth factor can eliminate the side effect of using after this reagent.
Embodiment 1: the present invention selects the result of the test of the reagent that the percentage by weight of TGF-1 3%, platelet derived growth factor 22%, epidermal growth factor 12%, Fn Fiberonectin 4%, vitronectin 2%, Protease-Activated Receptor 38%, interleukin-1 beta 2%, fibrin 2%, vascular endothelial cell growth factor 3% and islets of langerhans rope like growth factor 2% develops (percentage ratio in the present embodiment and following examples, the numerical value after its arithmetic point remains into after arithmetic point 1 with the counting mode rounding up) as shown in the table:
Wrinkle efficacy analysis while following up a case by regular visits to 3 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 6 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 9 months [example (%)]
Cicatrix curative effect:
Cicatrix efficacy analysis while at every turn following up a case by regular visits to [example (%)]
Wrinkle or cicatrix satisfaction evaluation [median (25% quantile, 75% quantile)]
The time of wrinkle or cicatrix appearance effect
| Wrinkle position | The time (moon) of average appearance effect | 95% credibility interval |
| Volume band | 3.1 | 2.6，4.3 |
| Crows-feet | 3.0 | 2.2，3.6 |
| Glabella stricture of vagina | 3.2 | 2.3，4.1 |
| Nasolabial fold | 3.0 | 2.2，4.0 |
| Perioral aging lines | 2.5 | 2.0，3.1 |
| Add up to | 3.0 | 2.6，3.3 |
| Depressed scar | 3.0 | 2.0，4.0 |
Embodiment 2: the present invention selects the result of the test of the reagent that the percentage by weight of TGF-1 6%, platelet derived growth factor 19%, epidermal growth factor 9%, Fn Fiberonectin 3%, glass adhesion egg 4%, Protease-Activated Receptor 37%, interleukin-1 beta 2%, fibrin 5%, vascular endothelial cell growth factor 2% and insulin like growth factor 3% develops as shown in the table:
Wrinkle efficacy analysis while following up a case by regular visits to 3 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 6 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 9 months [example (%)]
Cicatrix curative effect:
Cicatrix efficacy analysis while at every turn following up a case by regular visits to [example (%)]
Wrinkle or cicatrix satisfaction evaluation [median (25% quantile, 75% quantile)]
The time of wrinkle or cicatrix appearance effect
| Wrinkle position | The time (moon) of average appearance effect | 95% credibility interval |
| Volume band | 3.3 | 2.7，4.4 |
| Crows-feet | 3.2 | 2.3，3.7 |
| Glabella stricture of vagina | 3.4 | 2.4，4.3 |
| Nasolabial fold | 3.3 | 2.3，4.1 |
| Perioral aging lines | 2.7 | 2.1，3.3 |
| Add up to | 3.2 | 2.6，3.3 |
| Depressed scar | 3.2 | 2.1，4.2 |
Embodiment 3: the present invention selects the result of the test of the reagent that the percentage by weight of TGF-1 7%, platelet derived growth factor 23%, epidermal growth factor 11%, Fn Fiberonectin 2%, vitronectin 3%, Protease-Activated Receptor 32%, interleukin-1 beta 1%, fibrin 6%, vascular endothelial cell growth factor 1% and insulin like growth factor 4% develops as shown in the table:
Wrinkle efficacy analysis while following up a case by regular visits to 3 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 6 months [example (%)]
Wrinkle efficacy analysis while following up a case by regular visits to 9 months [example (%)]
Cicatrix curative effect:
Cicatrix efficacy analysis while at every turn following up a case by regular visits to [example (%)]
Wrinkle or cicatrix satisfaction evaluation [median (25% quantile, 75% quantile)]
The time of wrinkle or cicatrix appearance effect
| Wrinkle position | The time (moon) of average appearance effect | 95% credibility interval |
| Volume band | 3.5 | 2.9，4.6 |
| Crows-feet | 3.2 | 2.5，3.8 |
| Glabella stricture of vagina | 3.6 | 2.8，4.3 |
| Nasolabial fold | 3.4 | 2.6，4.2 |
| Perioral aging lines | 2.9 | 2.3，3.4 |
| Add up to | 3.2 | 2.8，3.6 |
| Depressed scar | 3.3 | 2.2，4.2 |
In order fully to investigate this technology in the curative effect and the untoward reaction that are widely used under condition, since in March, 2004, in Beijing, Shanghai, Nanning, Wenzhou, Xiamen Deng25Jia medical and beauty treatment mechanism carried out investigating widely to the efficacy and saferry of this technology, by in December, 2013, have the treatment that 1798 routine experimenters have accepted this technology, inject and within latter 3 months, 6 months, 9 months, 12 months, carry out follow-up observation, the 1508 routine patients that acceptance is followed up a case by regular visits to, except part after 3 example injections occurs that moderate is red and swollen, after 2 weeks, disappear.There is adverse events in Yu Wei, has shown good safety.
Claims (3)
1. one kind is applied to the injection reagent that beauty treatment is filled, it is characterized in that: include transforming growth factor-beta, platelet derived growth factor, epidermal growth factor, Fn Fiberonectin, vitronectin, Protease-Activated Receptor, interleukin-1 beta and cross-linking agent, each compositions in weight percentage is: transforming growth factor-beta 1 3%-17%; Platelet derived growth factor 19%-23%; Epidermal growth factor 9%-12%; Fn Fiberonectin 2%-4%; Vitronectin 2%-4%; Protease-Activated Receptor 32%-38%; Interleukin-1 beta 1%-2%; Cross-linking agent 2%-6%.
2. a kind of injection reagent that beauty treatment is filled that is applied to according to claim 1, it is characterized in that: also include vascular endothelial cell growth factor and insulin like growth factor, its compositions in weight percentage is: vascular endothelial cell growth factor 1%-3%; IMA-IGF2BP3-001 %-4%.
3. a kind of injection reagent that beauty treatment is filled that is applied to according to claim 1 and 2, is characterized in that: described cross-linking agent is fibrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410276414.7A CN104014000A (en) | 2014-06-10 | 2014-06-10 | Injection reagent for cosmetic filling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410276414.7A CN104014000A (en) | 2014-06-10 | 2014-06-10 | Injection reagent for cosmetic filling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104014000A true CN104014000A (en) | 2014-09-03 |
Family
ID=51431177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410276414.7A Pending CN104014000A (en) | 2014-06-10 | 2014-06-10 | Injection reagent for cosmetic filling |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104014000A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578775A (en) * | 2018-05-21 | 2018-09-28 | 白晋 | A kind of novel injectable composition for being applied to beauty filling |
| CN108653817A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of preparation and application of novel collagen stimulant |
| CN108728409A (en) * | 2018-06-01 | 2018-11-02 | 白晋 | A kind of self germinal layer fat mesenchymal competent cell extracting method and application |
| CN109431845A (en) * | 2018-11-26 | 2019-03-08 | 苏州先康科技有限公司 | A kind of combined type cosmetic formulation using stem cell |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080305517A1 (en) * | 2004-09-10 | 2008-12-11 | Aston University | Transglutaminase Crosslinked Collagen Biomaterial for Medical Implant Materials |
| WO2008157483A2 (en) * | 2007-06-14 | 2008-12-24 | The Research Foundation Of State University Of New York | Polypeptides and methods of use |
| WO2011024942A1 (en) * | 2009-08-28 | 2011-03-03 | 富士フイルム株式会社 | Matrix metalloprotease-2 (mmp-2) inhibitor |
| CN102008754A (en) * | 2010-12-14 | 2011-04-13 | 梁杰 | Cosmetic filler with long-term effectiveness capable of promoting soft tissue regeneration |
| CN103356706A (en) * | 2005-03-31 | 2013-10-23 | 斯丹姆涅恩有限公司 | Beautifying preparation for promoting non-scar healing or improving skin |
| CN103830768A (en) * | 2012-11-21 | 2014-06-04 | 深圳兰度生物材料有限公司 | Degradable wound repair material and preparation method thereof |
-
2014
- 2014-06-10 CN CN201410276414.7A patent/CN104014000A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080305517A1 (en) * | 2004-09-10 | 2008-12-11 | Aston University | Transglutaminase Crosslinked Collagen Biomaterial for Medical Implant Materials |
| CN103356706A (en) * | 2005-03-31 | 2013-10-23 | 斯丹姆涅恩有限公司 | Beautifying preparation for promoting non-scar healing or improving skin |
| WO2008157483A2 (en) * | 2007-06-14 | 2008-12-24 | The Research Foundation Of State University Of New York | Polypeptides and methods of use |
| WO2011024942A1 (en) * | 2009-08-28 | 2011-03-03 | 富士フイルム株式会社 | Matrix metalloprotease-2 (mmp-2) inhibitor |
| CN102008754A (en) * | 2010-12-14 | 2011-04-13 | 梁杰 | Cosmetic filler with long-term effectiveness capable of promoting soft tissue regeneration |
| CN103830768A (en) * | 2012-11-21 | 2014-06-04 | 深圳兰度生物材料有限公司 | Degradable wound repair material and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 施越冬等: "采用经碳化二亚胺交联的纤维蛋白凝胶作为可注射性软骨细胞支架材料的研究", 《中国临床医学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578775A (en) * | 2018-05-21 | 2018-09-28 | 白晋 | A kind of novel injectable composition for being applied to beauty filling |
| CN113244457A (en) * | 2018-05-21 | 2021-08-13 | 白晋 | Injection composition applied to beauty filling |
| CN108653817A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of preparation and application of novel collagen stimulant |
| CN108653817B (en) * | 2018-05-24 | 2021-02-02 | 上海其胜生物制剂有限公司 | Preparation method of novel collagen stimulant |
| CN108728409A (en) * | 2018-06-01 | 2018-11-02 | 白晋 | A kind of self germinal layer fat mesenchymal competent cell extracting method and application |
| CN109431845A (en) * | 2018-11-26 | 2019-03-08 | 苏州先康科技有限公司 | A kind of combined type cosmetic formulation using stem cell |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ter Horst et al. | Advances in keratinocyte delivery in burn wound care | |
| CN105125476B (en) | A kind of anti-wrinkle essence and preparation method thereof | |
| CN102229705B (en) | Collagen temperature-sensitive hydrogel and preparation method thereof | |
| Zou et al. | Fibroblasts: heterogeneous cells with potential in regenerative therapy for scarless wound healing | |
| Douglas | TGF-β in wound healing: a review | |
| Xu et al. | Autologous chyle fat grafting for the treatment of hypertrophic scars and scar-related conditions | |
| CN101791283B (en) | Cosmetic capable of eliminating striae gravidarum and scars | |
| CN104587518A (en) | Hyaluronic acid dressing and preparation method thereof | |
| CN104014000A (en) | Injection reagent for cosmetic filling | |
| Uhl et al. | Basic fibroblast growth factor accelerates wound healing in chronically ischaemic tissue | |
| Kokai et al. | Clinical evaluation of an off-the-shelf allogeneic adipose matrix for soft tissue reconstruction | |
| US20170260511A1 (en) | Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis, and the cultured skin made therefrom | |
| Xue et al. | Dermal fibroblast heterogeneity and its contribution to the skin repair and regeneration | |
| Choi et al. | Regulation of transforming growth factor β1, platelet-derived growth factor, and basic fibroblast growth factor by silicone gel sheeting in early-stage scarring | |
| CN105030647B (en) | A kind of preparation for reducing wrinkle and preparation method thereof | |
| KR20220049614A (en) | In vivo synthesis of elastic fiber | |
| CN103736080B (en) | For the preparation of wound healing, preparation method and its usage | |
| Li et al. | Advances of hydrogel combined with stem cells in promoting chronic wound healing | |
| Cass et al. | Scar wars: implications of fetal wound healing for the pediatric burn patient | |
| CN109988742A (en) | Autologous fibroblasts cultural method | |
| CN106344435A (en) | Skin protection cream capable of eliminating striae gravidarum | |
| Plotczyk et al. | Skin biology | |
| CN104524657A (en) | Method related to biological agent three-dimensional cosmetic injection | |
| CN104248644A (en) | Composite preparation capable of promoting restoration of skin wound due to diabetes and preparation method thereof | |
| Li et al. | Adipose stem cell secretion combined with biomaterials facilitates large-area wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140903 |